Latest Medical Devices News

Philips has officially declared compatibility for Imricor’s interventional MR devices with its magnetic resonance systems, enabling commercial clinical use and collaboration at a leading cardiology congress.

Resmed delivered a strong FY2026 with 10% revenue growth to $5.7 billion, a 17% rise in non-GAAP EPS, and a 10% dividend hike. Strategic moves include selling MatrixCare and acquiring Noctrix Health.

AVITA Medical posted robust Q2 2026 results with 18% revenue growth, driven by RECELL and supported by Cohealyx and PermeaDerm, and now expects to reach cash flow breakeven by year-end.

ReNerve has secured marketing approval for its NervAlign® Nerve Cuff in the Philippines, tapping into a major Southeast Asian market with significant nerve injury demand.

Osteopore has inked a three-year distribution agreement with Al-Umnia Medical to bring its 3D-printed orthopaedic implants to five Gulf countries, targeting a rapidly expanding regional market.

CurveBeam AI has launched a Share Purchase Plan offering eligible shareholders a 10% discount on new shares, aiming to raise up to $2 million alongside a pending $5 million placement.

Control Bionics has achieved FDA registration for its NeuroStrip surface EMG platform, cementing its medical device status in the US and bolstering its appeal in clinical and research markets.

Tissue Repair advances its US Phase III chronic wound trial with 100 patients randomised and targets October FDA 510(k) submission. The company reports a robust cash position bolstered by R&D refunds and has cut manufacturing scale-up costs.

EBR Systems advanced its wireless cardiac pacing rollout in Q2 2026, completing 46 implants and signing 17 new purchasing contracts while shifting focus to deeper utilisation within existing accounts.

OncoSil Medical reported a 53% increase in unit sales and advanced key regulatory approvals, including FDA final review and TGA listing, positioning it for growth in pancreatic cancer treatment.

Epiminder has leveraged its $125 million IPO to advance clinical enrolments, boost Medicare reimbursement, and develop its next-generation Minder device, positioning for a commercial launch in early 2028.

PainChek lifted implemented ARR by 5.9% to $4.46 million and secured its first US commercial contracts under a major Sabra REIT agreement, boosting customer receipts 27% in the June quarter.